pay particular attention to parking lots and garages as well as street level parking adjacent to the buildings. In a number of cases, restrictions have been placed on parking next to buildings.

We are committed to continuing these interim heightened security measures through September 30, and are taking steps to maintain these initiatives in FY 1996 until GSA begins implementation of updated security provisions identified in the DOJ study.

I would like to specifically recognize the efforts of the FPS in implementing and maintaining the heightened interim security measures during the past four months. I would also like to commend the entire agency for pulling together to accomplish the enormous task involved in dealing with the devastation of the bombing in Oklahoma City as well as the ensuing operational requirements. Most assuredly this task has been a difficult one, but the tremendous accomplishments of those involved is a fitting tribute to the dedication and professionalism of GSA employees nationwide.

GSA is well on its way to completing the task assigned by the President, and identifying the security needs of its facilities nationwide. To date, we have established Building Security Committees (BSC's) at the higher risk Level IV buildings. The BSC's are meeting and will identify the required security upgrades as outlined in the DOJ report. We continue to maintain the ambitious schedule established by the President. FPS will be monitoring the Level IV BSC activities, and developing guidelines for reporting and evaluating their security recommendations.

The DOJ report specifically stated that the FPS ''has the experience and the historical charter to provide security services'' in GSA federal buildings by using a wide range of technical and human resources (including both Federal Protective Police Officers (FPPO's) and contract security guards). Finally, an Executive Order establishing an Interagency Security Committee (ISC) headed by the Assistant Commissioner of the FPS has been signed, and the President is issuing a Memorandum for Executive Departments and Agencies recognizing GSA's leadership role in federal building and facility security.

The next few months will be both demanding and challenging as GSA and FPS endeavor to meet the Presidents ambitious schedule for implementing the DOJ study recommendations. During this time, I would ask everyone to remain committed to GSA's mission and responsibility to provide a safe and secure working environment for our clients, customers and visitors.

Dated: August 15, 1995.

Roger W. Johnson,

Administrator.

[FR Doc. 95–21223 Filed 8–25–95; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Medical Classification Systems and NCVHS Subcommittee on Ambulatory and Hospital Care Statistics: Meeting

Pursuant to Pub. L. 92–463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following meeting.

Name: NCVHS Subcommittee on Medical Classification Systems and NCVHS Subcommittee on Ambulatory and Hospital Care Statistics.

Time and Date: 9 a.m.–1 p.m., September 15, 1995.

Place: Room 503A, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Medical Classification Systems and the Subcommittee on Ambulatory and Hospital Care Statistics will meet jointly in a working session to discuss the final report of the compendium on person-level and event-level health care core data sets and to plan the NCVHS public meetings to obtain input from diverse parties who report and use standardized core data sets for enrollment and encounters; to receive an update on the NCHS Morbidity Classification Branch activities; and to review the subcommittees' work plans for 1995–1996.

CONTACT PERSON FOR MORE INFORMATION: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436–7050.

Dated: August 22, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC)

[FR Doc. 95–21255 Filed 8–25–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0272]

Drug Export; Telfast (Fexofenadine Hydrochloride) Tablets 60 Milligrams (mg)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Marion Merrell Dow Inc., has filed an application requesting conditional approval for the export of the human drug Telfast (fexofenadine hydrochloride) tablets 60 (mg) to France for packaging for transshipment to the United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD–310), Food and Drug Administration, 7520 Standish Place, Rockville, MD 20855, 301–594–3150.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Marion Merrell Dow Inc., Marion Park Dr., P.O. Box 9627, Kansas City, MO, 64134–0627, has filed an application requesting conditional approval for the export of the human drug Telfast (fexofenadine hydrochloride) tablets 60 mg to France for packaging for transshipment to the United Kingdom. Telfast (fexofenadine hydrochloride)